[miR-2110 Affects the Biological Behaviors of Lung Adenocarcinoma by Regulating CDT1]

Overview

Journal Sichuan Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2024 Nov 7

PMID 39507968

Authors

Yuan Mi

Xuzhe Li

Cong Wang

Chenxi Lin

Zhichao Zhao

Xiaofei Yan

Ping Shi

Lei Wang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the effect of miR-2110 on the biological behaviors, such as cell proliferation, apoptosis, and metastasis, of lung adenocarcinoma (LUAD) cells by means of cell and animal experiments.

Methods: Bioinformatics websites, including ENCORI, TargetScan, miRTarBase, and Tarbase, were used to analyze the changes in the expression of miR-2110 in LUAD samples and to predict miR-2110 target. LUAD tissue samples and cells were collected and the changes in the expression of miR-2110 were verified through PCR technology. CCK-8 assay, clonogenic assay, Transwell assay, and flow cytometry were conducted to analyze alterations in the functions of LUAD cells. In addition, 10 BALB/c female nude mice aged 6 to 8 weeks were randomly divided into 2 groups, and the effect of miR-2110 on LUAD was investigated by experiments.

Results: miR-2110 was significantly decreased in LUAD tissues and cells compared with the normal lung tissues. miR-2110 overexpression inhibited the proliferation and metastasis of LUAD cells and promoted the apoptosis of tumor cells (<0.05). Bioinformatics prediction and dual luciferase reporter gene assay results confirmed that miR-2110 could target and bind to CDT1. In addition, overexpression of gene reversed the proliferation, metastasis, and apoptosis of miR-2110 compared with the miR-2110 overexpression group (<0.05). Nude mice experiments showed that miR-2110 overexpression significantly decreased the expression of Ki67, a tumor proliferation index, and vimentin and MMP9, two metastasis indices, compared with the control group.

Conclusion: miR-2110 can inhibit proliferation and metastasis of LUAD by targeting CDT1, providing a new rationale for the treatment of LUAD.

References

Son S, Yun J, Kim D, Jung Y, Han S, Lee Y . MicroRNA 29a therapy for CEACAM6-expressing lung adenocarcinoma. BMC Cancer. 2023; 23(1):843. PMC: 10492333. DOI: 10.1186/s12885-023-11352-w. View

Yousefi M, Jalilian H, Heydari S, Seyednejad F, Mir N . Cost of Lung Cancer: A Systematic Review. Value Health Reg Issues. 2022; 33:17-26. DOI: 10.1016/j.vhri.2022.07.007. View

Fang S, Peng L, Zhang M, Hou R, Deng X, Li X . MiR-2110 induced by chemically synthesized cinobufagin functions as a tumor-metastatic suppressor via targeting FGFR1 to reduce PTEN ubiquitination degradation in nasopharyngeal carcinoma. Environ Toxicol. 2024; 39(6):3548-3562. DOI: 10.1002/tox.24197. View

Zhang B, Wang D, Wang Y, Chen G . miRNA-338-3p inhibits the migration, invasion and proliferation of human lung adenocarcinoma cells by targeting MAP3K2. Aging (Albany NY). 2022; 14(15):6094-6110. PMC: 9417240. DOI: 10.18632/aging.204198. View

Kim J, You H, Youn C . SCARA3 inhibits cell proliferation and EMT through AKT signaling pathway in lung cancer. BMC Cancer. 2022; 22(1):552. PMC: 9112459. DOI: 10.1186/s12885-022-09631-z. View

Nakanishi T, Yoneshima Y, Okamura K, Yanagihara T, Hashisako M, Iwasaki T . MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma. Cancer Sci. 2023; 114(10):4101-4113. PMC: 10551600. DOI: 10.1111/cas.15921. View

Zhao Z, Partridge V, Sousares M, Shelton S, Holland C, Pertsemlidis A . microRNA-2110 functions as an onco-suppressor in neuroblastoma by directly targeting Tsukushi. PLoS One. 2018; 13(12):e0208777. PMC: 6294380. DOI: 10.1371/journal.pone.0208777. View

Jiang X, Li Y, Zhang N, Gao Y, Han L, Li S . RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma. Cell Biosci. 2021; 11(1):74. PMC: 8051110. DOI: 10.1186/s13578-021-00586-5. View

Majidpoor J, Mortezaee K . Steps in metastasis: an updated review. Med Oncol. 2021; 38(1):3. DOI: 10.1007/s12032-020-01447-w. View

10.

Shan J, An Y, Bues M, Schild S, Liu W . Robust optimization in IMPT using quadratic objective functions to account for the minimum MU constraint. Med Phys. 2017; 45(1):460-469. PMC: 5774242. DOI: 10.1002/mp.12677. View

11.

Pinto R, Petriella D, Lacalamita R, Montrone M, Catino A, Pizzutilo P . KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy. Cancers (Basel). 2019; 11(8). PMC: 6721568. DOI: 10.3390/cancers11081145. View

12.

Han Y, Ma D, Lee S, Mao Y, Sun S, Jin M . Bioinformatics Analysis of Novel Targets for Treating Cervical Cancer by Immunotherapy Based on Immune Escape. Cancer Genomics Proteomics. 2023; 20(4):383-397. PMC: 10320560. DOI: 10.21873/cgp.20390. View

13.

Zhang L, Bai J, Hu Y, Zhou D, Zheng Q, Yin C . [MiR-204 inhibits invasion and metastasis of breast cancer cells by targeted regulation of HNRNPA2B1]. Nan Fang Yi Ke Da Xue Xue Bao. 2020; 40(6):869-875. PMC: 7321266. DOI: 10.12122/j.issn.1673-4254.2020.06.15. View

14.

Zhu J, Pfuhl T, Motsch N, Barth S, Nicholls J, Grasser F . Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J Virol. 2009; 83(7):3333-41. PMC: 2655542. DOI: 10.1128/JVI.01689-08. View

15.

He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi S . miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci. 2020; 16(14):2628-2647. PMC: 7415433. DOI: 10.7150/ijbs.47203. View

16.

Ferracin M, Lupini L, Salamon I, Saccenti E, Zanzi M, Rocchi A . Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget. 2015; 6(16):14545-55. PMC: 4546486. DOI: 10.18632/oncotarget.3859. View

17.

Tanigawa K, Tomioka Y, Misono S, Asai S, Kikkawa N, Hagihara Y . Minichromosome maintenance proteins in lung adenocarcinoma: Clinical significance and therapeutic targets. FEBS Open Bio. 2023; 13(9):1737-1755. PMC: 10476565. DOI: 10.1002/2211-5463.13681. View

18.

Li H, Chen Z, Chen N, Fan Y, Xu Y, Xu X . Applications of lung cancer organoids in precision medicine: from bench to bedside. Cell Commun Signal. 2023; 21(1):350. PMC: 10698950. DOI: 10.1186/s12964-023-01332-9. View

19.

Zhang X, Li F, Zhou Y, Mao F, Lin Y, Shen S . Long noncoding RNA AFAP1-AS1 promotes tumor progression and invasion by regulating the miR-2110/Sp1 axis in triple-negative breast cancer. Cell Death Dis. 2021; 12(7):627. PMC: 8213778. DOI: 10.1038/s41419-021-03917-z. View